Sandra and Edward Meyer Cancer Center

A common, spontaneous mutation in blood stem cells, which has been linked to higher risks of blood cancer and cardiovascular disease, may promote these diseases by altering the stem cells’ programming of gene activity and the mix of blood cells they produce.

Weill Cornell Medicine has been awarded a $1 million, three-year grant from the Department of Defense’s Kidney Cancer Research Program to fund research on the role of the protein ATF4 in clear cell renal cell carcinoma (ccRCC), a form of kidney cancer.

Dr. Jedd Wolchok, an internationally acclaimed medical oncologist whose innovations in immunotherapy have revolutionized melanoma treatment, has been recruited as the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, effective Sept. 12.

Dr. Steven Josefowicz, an assistant professor in the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine, has won a 2022 Investigators in the Pathogenesis of Infectious Disease (PATH) award from the Burroughs Wellcome Fund.

A large clinical trial among people living with HIV has found that treating anal precancerous lesions cuts the risk of developing anal cancer by 57 percent compared with active monitoring with no treatment.

Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.

DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people with a mutation in a gene called SETD2, leading to a type of aggressive blood cancer.

Immunotherapy unleashes the power of the immune system to fight cancer. However, for some patients, immunotherapy doesn’t work, and new research may help explain why. 

Cancer cells can disrupt a metabolic pathway that breaks down fats and proteins to boost the levels of a byproduct called methylmalonic acid, thereby driving metastasis, according to research led by scientists at Weill Cornell Medicine.

A multi-institutional group in New York City has united to address health disparities in multiple chronic diseases through a new collaborative center.

A protein that masterminds the way DNA is wrapped within chromosomes has a major role in the healthy functioning of blood stem cells, which produce all blood cells in the body, according to a new study from researchers at Weill Cornell Medicine.

Melanoma cells release small extracellular packages containing the protein nerve growth factor receptor, which primes nearby lymph nodes for tumor metastases, according to a new study by Weill Cornell Medicine investigators.

A new protein variant underlies the ability of gastric cancers to resist an otherwise effective family of chemotherapy drugs, according to a study by a multidisciplinary team at Weill Cornell Medicine. The results suggest a treatment strategy that could improve the prognoses of many patients with cancer.

Treatment with arginine, one of the amino-acid building blocks of proteins, enhanced the effectiveness of radiation therapy in cancer patients with brain metastases, in a proof-of-concept, randomized clinical trial from investigators at Weill Cornell Medicine and Angel H. Roffo Cancer Institute.

Lymphomas can turbo-charge their ability to proliferate by crowding growth-supporting enzymes into highly concentrated compartments within tumor cells, according to a study led by researchers at Weill Cornell Medicine.

A team led by researchers at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School, Massachusetts General Hospital and the Broad Institute of MIT and Harvard has profiled in unprecedented detail thousands of individual cells sampled from patients’ brain tumors.

Turning off a defense mechanism that protects colorectal cancer tumors from being discovered by immune cells could be a possible strategy for treating the disease.

The master regulator behind the development of antibody-producing cells has been identified in a study by investigators at Weill Cornell Medicine. The findings provide new insight into the inner workings of the immune system and may help understand how tissues develop and how certain cancers arise.

A team co-led by scientists at Weill Cornell Medicine has revealed in detail how the most common primary eye cancer in adults, uveal melanoma (UM), can progress from a slow-growing, “indolent” state to a lethal metastasizing state. The discovery is a significant advance in fundamental cancer research that also suggests new strategies for treatment.

Treatment with a ready-made preparation of human immune cells helps prevent infections in people whose immune systems are temporarily weakened by leukemia treatment.